For comments, suggestions
Created with Raphaël 2.1.0 24.10.2017 Filing date 28.05.2019 Validation fee payment 31.10.2019 (A1) Patent application published 22.07.2021 AGEPI application filing date 30.09.2021 (T2) Translation of the validated European patent 01.05.2025 24.10.2025 Valid until 25.10.2026 Renewal fee to be paid until 24.10.2037 Patent will expire on

Patent in force


(210)Number of the EPO application17794593
(220)Filing date of the EPO application2017.10.24
(80)EPO patent specification publication (B)EPB nr. 18/2021, 2021.05.05
(110)EPO patent number3532499
(11)Number of the documentMD 3532499 T2
(21)Number of the applicatione 2019 0980
(71)Name(s) of applicant(s), code of the countryELI LILLY AND COMPANY, US;
(72)Name(s) of inventor(s), code of the countryBENSCHOP Robert Jan, US;
DAVIES Julian, US;
OKRAGLY Angela Jeannine, US;
PATEL Chetankumar Natvarlal, US;
TRUHLAR Stephanie Marie, US;
(73)Name(s) of owner(s), code of the countryELI LILLY AND COMPANY, US;
(54)Title of the inventionAnti-IL-33 antibodies and uses thereof
(13)Kind-of-document code T2
(51)International Patent Classification A61P 1/00 (2006.01.01); A61P 11/00 (2006.01.01); A61P 11/06 (2006.01.01); A61P 17/00 (2006.01.01); C07K 16/24 (2006.01.01); A61P 37/08 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2019.10.31
(49)Date of publication of the translation of the validated European patent specification2021.09.30
(30)Priority201662414258 P, 2016.10.28, US
(74)Patent attorney(Procedură) LAZICOV Tatiana, str. A. Pușkin nr. 33, ap. 73, MD-2012, Chișinau, Republica Moldova
(86)International applicationPCT/US2017/058020, 2017.10.24
(87)International publicationWO 2018/081075, 2018.05.03
Up
/Inventions/details/3532499